UPC Agreement Is Not EU Law, No Referrals to CJEU

​
September 1, 2025

expert v. Seoul Viosys, UPC_CoA_380/2025

Order of 20 August 2025 (ORD_22147/2025)[1]

This order from the UPC Court of Appeal clearly states that the Court of Justice of the EU cannot be asked to interpret the UPC Agreement and Rules of Procedure. The order also sets out the circumstances in which a referral to the Court of Justice of the European Union (CJEU) might be made by the UPC and reiterates the need for parties to stick to the time limits specified in the Rules of Procedure.

The appeal arose from a decision of the Düsseldorf LD rejecting an application for costs by expert as inadmissible. The application for costs was brought outside the one-month time limit specified for such applications in the Rules of Procedure[2].

With its appeal, expert requested that the one-month period set out in the Rules of Procedure be extended and, as a precautionary measure, requested that the Court of Appeal refer questions to the CJEU. In essence, the requested referral was intended to resolve an alleged contradiction between the time limit imposed by the Rules of Procedure and the right of the successful party to seek reimbursement for its costs from the unsuccessful party, as set out in the UPC Agreement[3].

On its main request, expert was unsuccessful. The Court of Appeal referred to its earlier decision in Hanshow v. VusionGroup[4], where the court stated that failure to meet the one-month deadline for an application for a cost decision can only be remedied through re-establishment of rights[5], not through a retrospective extension of the deadline.

On the question of a referral, the Court of Appeal clearly stated that the CJEU cannot be asked to interpret the UPC Agreement or the Rules of Procedure. The Agreement is not a regulation, a directive, a decision, a recommendation or an opinion, nor is it an act of the institutions, bodies, offices or agencies of the Union. Indeed, the Court of Appeal considered it clear from CJEU case law that the UPC Agreement is an international agreement forming part of international law.

The Court of Appeal also considered whether the time limit specified in the Rules of Procedure is compatible with EU law. It concluded that it is, and that the correct interpretation of EU law on time limits is so obvious that it leaves no room for any reasonable doubt, making a referral to the CJEU on the compatibility of the Rule of Procedure with EU law unnecessary.

Nevertheless, the Court of Appeal set out a series of clear examples of when a referral may be appropriate:

  • When a provision of the UPCA or the RoP implements or relates to a directive, a regulation, or to an international agreement such as the Lugano Convention where the EU is a contracting party, whether the UPCA and/or the RoP make specific reference thereto or not. The EU legislation referred to in the UPCA and the RoP is not exhaustive.
  • When the UPC applies EU law.
  • When assessing the compatibility of the UPC Agreement and Rules of Procedure with EU law.

However, even in these situations, a referral will not automatically be made. So far, the UPC has not made any referrals to the CJEU, even when issues specific to EU law come up, as in Aylo v. Dish[6]. In that case, the court was asked but declined to refer a question to the CJEU regarding jurisdiction and the application of the Brussels I recast regulation.

The present order sets out very clearly that referrals will not be made to the CJEU for the purpose of interpreting the UPC Agreement or Rules of Procedure. This means that referrals to the CJEU are likely to be rare in practice, only arising when there is a question of EU law or when the compatibility of the UPC Agreement or Rules of Procedure with EU law is unclear.

[1] https://www.unifiedpatentcourt.org/en/node/137181

[2] Rule 151 RoP: "Where the successful party… wishes to seek a cost decision, it shall within one month of service of the decision lodge an Application for a cost decision…"

[3] Article 69 UPCA: "Reasonable and proportionate legal costs and other expenses incurred by the successful party shall, as a general rule, be borne by the unsuccessful party…"

[4] https://www.unifiedpatentcourt.org/en/node/125743, UPC_CoA_618/2024, decision of 6 June 2025 (ORD_69091/2024)

[5] Rule 320 RoP: "Where a party has failed to observe a time-limit set by these Rules or the Court for a cause which, despite all due care having been taken by the party…"

[6] UPC_CoA_188/2024, order of 3rd September 2024 ORD_42716/2024, as reported here: https://eip.com/uk/latest/article/upc_court_of_appeal_clarifies_jurisdiction_on_indirect_infringement/

The Latest Thought Leadership pieces in the Content Hub

UPC Considers but does not decide exhaustion of rights in relation to consumables
October 30, 2025
Brita v. Aquashield UPC CFI 248/2024 (Munich LD), decision of 22 August 2025[1] UPC CFI 564/2024 (Munich LD), decision of 16 October 2025[2] Brita sued Aquashield and others for infringement of...
UPC takes strict approach on costs reimbursement
October 30, 2025
Insulet v. EOFlow UPC_CFI_773/2025 and UPC_CFI 774/2025 (Milan CD), decision of 15 October 2025[1] The dispute began when Insulet sought a provisional injunction against EOFlow to prevent...
Unconventional Service: igus v. Whale Technology
August 29, 2025
UPC_CFI_318/2025, decision of 5 August 2025 (ORD_34299/2025)[1] In a default judgment issued by the Düsseldorf Local Division of the Unified Patent Court, Whale Technology (Shanghai) Co., Ltd.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​